New report provides glimpse into security of an Alzheimer’s drug

Good morning, everybody, and the way are you at present? We’re doing simply high-quality, thanks, regardless of a thick fog enveloping the Pharmalot grounds. In any case, because the Morning Mayor taught us: “Each new day needs to be unwrapped like a treasured reward.” So whilst you tug on the ribbon, we are going to hearth up our espresso kettle to brew one other cup of stimulation. Our selection at present is chocolate cappuccino, for these monitoring this type of factor. It pays to experiment, you understand? In the meantime, we have now assembled the newest menu of tidbits so that you can peruse as you gear up for one more busy day. We hope your journey goes effectively and also you conquer the world. And as all the time, do keep up a correspondence. …

Investigators launched the primary detailed case report a few affected person who died after receiving lecanemab, offering a brand new glimpse into security issues surrounding the intently watched experimental Alzheimer’s drug, STAT writes. An unpublished model of the report was previously written about by Science in November, one among three deaths from the lecanemab trials revealed by Science and STAT. However the published version, within the New England Journal of Medication, will permit docs to guage the case as they think about whether or not and find out how to use a remedy that might be permitted by the U.S. Meals and Drug Administration as quickly as this week.